How Has the Acute Bacterial Skin And Skin Structure Infections Market Size Evolved in Recent Years?
The acute bacterial skin and skin structure infections market has seen considerable growth due to a variety of factors.
• In the past few years, the market size for acute bacterial skin and skin structure infections has seen robust growth. The projected growth is from $11.75 billion in 2024 rising to $13.03 billion in 2025, reflecting a compound annual growth rate (CAGR) of 10.9%.
This growth during the historic period can be linked to a number of factors such as innovations within the healthcare industry, economic influences, patient population trends, advancements in diagnostic methods, as well as forward-thinking clinical trial practices.
What are the Market Size and Expected Growth Rates for the Acute Bacterial Skin And Skin Structure Infections Market?
The acute bacterial skin and skin structure infections market is expected to maintain its strong growth trajectory in upcoming years.
• The acute bacterial skin and skin structure infections market size is expected to see strong growth in the next few years. It will grow to $18.99 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%.
The growth in the forecast period can be attributed to global epidemiological factors, market entry of new therapies, rapid diagnostic tools, patient-centric approach, shifting treatment guidelines. Major trends in the forecast period include patient population demographics, antibiotic resistance concerns, advancements in treatment strategies, prevalence of methicillin-resistant staphylococcus aureus (mrsa), focus on outpatient treatment.
What Are The Core Factors Supporting Growth In The Acute Bacterial Skin And Skin Structure Infections Market?
An escalation in skin infection cases is anticipated to boost the growth of the acute bacterial skin and skin structure infections market. Skin infections involve the invasion and multiplication of microorganisms like bacteria, fungi, or viruses within the skin, causing varying symptoms and discomfort. The escalation in these infections necessitates a higher demand for therapeutic solutions, antibiotics, and innovative treatments for acute bacterial and skin structure infections, ensuring optimal care and positive patient outcomes. For instance, the World Health Organization reported in March 2023 that about 1.8 billion people worldwide are afflicted with skin conditions at any given time. Neglected tropical diseases account for about 10% of these, while fungal infections and bacterial infections account for 34% and 23% respectively, often resulting in high mortality rates. Thus, the escalating prevalence of skin infections is projected to drive the growth of the acute bacterial skin and skin structure infections market. Chronic disease prevalence is increasing and this is projected to drive the growth of the acute bacterial skin and skin structure infections market further. Chronic diseases are long-term medical conditions that are typically slowly progressing and persistent over a lengthy period. These conditions, which often last for multiple years or even a lifetime, typically do not resolve independently. Increased cases of chronic diseases elevate the risk of bacterial skin infections, necessitating heightened levels of treatments, hospitalizations, specialized care, research, awareness programs, healthcare expenditure, and customized interventions for those affected. The World Health Organization noted in September 2022 that global deaths caused by non-communicable diseases or chronic diseases accounted for 74%--making a total of 41 million deaths per year. Cardiovascular diseases caused 17.9 million deaths, cancer caused 9.3 million deaths, chronic respiratory diseases resulted in 4.1 million deaths, and finally diabetes caused 2.0 million deaths. Consequently, the rising prevalence of chronic diseases is anticipated to propel the growth of the acute bacterial skin and skin structure infections market.
What Are The Key Segments Within The Global Acute Bacterial Skin And Skin Structure Infections Market?
The acute bacterial skin and skin structure infections market covered in this report is segmented –
1) By Type Of Infection: Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections, Community-Acquired Acute Bacterial Skin And Skin Structure Infections
2) By Active Ingredients: Delafloxacin, Vancomycin, Ceftaroline Fosamil, Oritavancin, Tedizolid, Daptomycin, Tigecycline, Linezolid, Other Active Ingredients
3) By Route Of Administration: Oral, Parenteral, Topical
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By Application: Cellulitis, Abscess, Surgical Wounds, Traumatic Wound
Subsegments:
1) By Hospital-Acquired Acute Bacterial Skin And Skin Structure Infections (HABSSSIs): Surgical Site Infections, Catheter-Related Infections, Pressure Ulcers, Infections Related To Medical Devices
2) By Community-Acquired Acute Bacterial Skin And Skin Structure Infections (CABSSSIs): Cellulitis, Abscesses, Impetigo, Folliculitis, Wound Infections
Pre-Book The Acute Bacterial Skin And Skin Structure Infections Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Impacting The Size Of The Acute Bacterial Skin And Skin Structure Infections Market?
Leading businesses in the acute bacterial skin and skin structure infections market are striving to create innovative single-dose treatments, such as Dalbonova, to maintain an advantageous position in the industry. Dalbonova is a convenient and effective single-dose treatment that enables patients to get their expected outcomes with just one powerful 1500 mg dose given once. For example, in August 2023, BDR Pharmaceuticals Internationals Pvt. Ltd., a pharmaceutical firm from India that specializes in API (active pharmaceutical ingredient) and formulation therapeutic segments, including acute bacterial skin and skin structure infections, introduced the Dalbonova injection. This single-dose treatment for acute bacterial skin and skin structure infections (ABSSSI) lessens the chance of contracting diseases in the hospital by providing a single-dose solution and avoiding the necessity of hospital stays. It is developed to cure acute bacterial skin and skin structure infections (ABSSSI) brought on by specific gram-positive microorganisms in patients of all ages, including newborns.
Who Are the Key Players In The Acute Bacterial Skin And Skin Structure Infections Market?
Major companies operating in the acute bacterial skin and skin structure infections market report are:
• Pfizer Inc.
• AbbVie Inc.
• Novartis AG
• Abbott Laboratories
• Fresenius SE & Co. KGaA
• GSK PLC
• Takeda Pharmaceutical Company Limited
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Limited
• Menarini Group
• Dr. Reddy's Laboratories Ltd.
• Cipla Limited
• Aspen Pharmacare Holdings Limited
• Lupin Limited
• Zydus Lifesciences Limited
• Eurofarma Laboratórios S.A.
• Glenmark Pharmaceuticals Ltd.
• Jiangsu Hansoh Pharmaceutical Group Co. Ltd.
• Alkem Laboratories Limited
• Zhejiang Huahai Pharmaceutical Co. Ltd.
• Zhejiang Medicine Co. Ltd.
• Aurobindo Pharma Limited
• Zhejiang Jingxin Pharmaceutical Co. Ltd.
• ACS Dobfar SpA
• Melinta Therapeutics LLC
• Shandong Luoxin Pharmaceutical Group Co. Ltd.
• Wakunaga Pharmaceutical Co. Ltd.
• Flynn Pharma Ltd.
What Are The Regional Insights Into The Acute Bacterial Skin And Skin Structure Infections Market?
Asia-Pacific was the largest region in the acute bacterial skin and skin structure infections market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the acute bacterial skin and skin structure infections market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
